



INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE

Harvest Healthcare Leaders Income ETF

June 30, 2020



The Fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure, can be obtained at your request, and at no cost, by calling us at 1-866-998-8298; by writing to us at Harvest Portfolios Group Inc., 610 Chartwell Rd, Suite 204, Oakville, Ontario, L6J 4A5; by visiting our website at www.harvestportfolios.com; or on SEDAR at www.sedar.com.

Harvest Healthcare Leaders Income ETF

CORPORATE OVERVIEW

Harvest Portfolios Group Inc. (“Harvest” or the “Manager”) is a Canadian Investment Manager founded in 2009. Harvest is focused on developing investment products that follow three investment criteria.

We (i) endeavor to develop investment products that are clear in their mandate and easy for investors to understand, (ii) strive to be transparent so that our investors can review their financial reports and know exactly what they own and (iii) seek to provide investors with consistent monthly or quarterly income by investing the fund portfolios in well managed companies that have a steady cash flow and dividend-paying history.

INVESTMENT PRODUCT

The Harvest Healthcare Leaders Income ETF (the “Fund”) invests in an equally-weighted portfolio of 20 Equity Securities¹ that are included in the Health Care sector of the Global Industry Classification Standards¹ or, if such industry classification system is no longer made available by MSCI Inc. and Standard & Poor’s, any other internationally recognized industry classification system at the time of investment and whose underlying business includes, but is not limited to, the provision of healthcare goods and services, including manufacturing and distributing healthcare products, equipment, supplies and technologies, producing and marketing of pharmaceuticals and biotechnology products, and/or engaging in research and development, each with a market capitalization of at least US\$5 billion.

¹ As defined in the Fund’s prospectus dated June 15, 2020.

Harvest Healthcare Leaders Income ETF

MANAGEMENT DISCUSSION OF FUND PERFORMANCE

The interim management report of fund performance contains financial highlights but does not contain the complete interim financial statements of the Fund. For your reference, the interim financial statements of the Fund are attached to the interim management report of fund performance. You may obtain additional copies of these documents at your request, and at no cost, by calling toll free at 1-866-998-8298; by writing to us at Harvest Portfolios Group Inc., 610 Chartwell Rd, Suite 204, Oakville, Ontario, L6J 4A5; or by visiting our website at www.harvestportfolios.com; or on SEDAR at www.sedar.com.

Unitholders may also contact us using one of these methods to request a copy of the Fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

INVESTMENT OBJECTIVES AND STRATEGY

The Fund has been created to provide investors with a unique exposure to a portfolio of Equity Securities that are included in the Health Care sector of the Global Industry Classification Standards (or, if such industry classification system is no longer made available by MSCI Inc. and Standard & Poor's (or, if applicable, any successor of either of these entities), any other internationally recognized industry classification system at the time of investment and whose underlying business includes, but is not limited to, the provision of healthcare goods and services, including manufacturing and distributing healthcare products, equipment, supplies and technologies, producing and marketing of pharmaceuticals and biotechnology products, and/or engaging in research and development, each with a market capitalization of at least US\$5 billion.

The Fund's investment objectives are to provide unitholders with:

- (i) the opportunity for capital appreciation; and
- (ii) monthly cash distributions.

To achieve its investment objectives, the Fund will invest in an equally-weighted portfolio of Equity Securities of 20 Healthcare Issuers¹ from the Healthcare Leaders Investable Universe¹ that have a market capitalization of at least US\$5 billion at the time of investment and meet the investment characteristics described below. In order to seek to generate additional returns, the Manager will sell call options on no more than 33% of the Equity Securities of each Healthcare Issuer held in the Fund.

Harvest will quarterly reconstitute and rebalance the Portfolio such that, at the time of the initial investment and immediately following each quarterly reconstitution and rebalancing, will have the following investment characteristics:

- Value** – An average Price-to-Earnings ratio lower than the average for the Healthcare Leaders Investable Universe; and
- Quality** – An average 5-year Return on Equity greater than the average for the Healthcare Leaders Investable Universe.

RISK

The risks associated with investing in the Fund are as described in the prospectus. There were no material changes to the Fund over the period that affected the overall level of risk of the Fund.

RESULTS OF OPERATIONS

The Fund returned -3.95% for Series A and -2.83% for Series U compared to the MSCI World Health Care Net Total Return Index (USD) of 1.41% for the period ending June 30, 2020. The primary reason for the divergence is that the index is market capitalization weighted, holds companies that do not have liquid options and hold international positions that are priced in foreign currency and the index is not currency hedged. The return for Series B is not presented because it commenced operation on March 10, 2020 and has not been in existence for one year.

The three primary drivers for the sectors outlook are: Aging populations, technological innovation (devices and drugs) and growth from developing markets, where there is a disproportionate share of increased wealth expended on healthcare needs. These medium to longer term drivers remain in-tact and form the basis of our longer-term positive view on the sector. Over the past several years, the sector has had several headwinds driven in large part by sentiment towards the sector having been muted driven by the political rhetoric in the United States as they grapple with rising out of pocket healthcare expenditures. Concerns and volatility were exacerbated as extreme left candidate Bernie Sanders gained in the polls to be the US Democratic presidential candidate through early 2020. While his proposals to eliminate private healthcare insurers and all but nationalize drug production we believe would not be practicably implemented, this caused further volatility early in the year.

¹ As defined in the Fund's prospectus dated June 15, 2020.

Harvest Healthcare Leaders Income ETF

The unprecedented global pandemic that quickly erupted through the end of February caused significant disruptions to the markets and equally caused volatility levels, both realized and implied, to expand to extreme levels in many cases not seen even during the financial crisis of 2008. Uncertainty over the systemic disruptions and timing of any return to normalcy kept volatility at extreme levels for several months. The volatility and uncertainty were met swiftly with significant and in many countries, unprecedented stimulus, both monetary and fiscally. This allowed credit markets to stay fluid and provided some stability to the broader economic systems and resulted in overall extreme volatility subsiding toward early summer. However, uncertainty remains as to the duration and longer-term economic impact of the pandemic and systemic shutdowns. This coincides with volatility levels that remain elevated compared to recent years, but below the peaks that were seen early in the pandemic.

There have been several key areas of the market that have been hit relatively hard by the pandemic. Tourism, brick & mortar retail and travel related businesses have been particularly hard hit. However, some areas of the market have proven more resilient and are well positioned for the current environment as we look towards the near to medium term. While the technology sector has had the most apparent impact from the global pandemic, driven by work from home, online consumerism and increased security needs, Healthcare has similarly had several key positive drivers that are coming to the surface.

Firstly, the fact Joe Biden emerged as the dominant candidate for Democratic nominee for president, has all but eliminated a very low probability, but noisy and disruptive environment with a Bernie Sanders nominee. Secondly, the immediate response by the industry to mobilize significant capital and human capital quickly and efficiently highlights their commitment to finding treatments and potential vaccines. From a sentiment perspective, we believe this shifts the perception and dialogue away from high prices towards their potential ability to effectively return the world back from an environment that has been highly disruptive to the global populations, to a more normal, pre-pandemic environment. In past cycles, Healthcare known for its superior good status, has often performed well during uncertain times. Particularly for the drug manufacturers, the necessity of their goods during robust economic times and during recessions, provides some for insights and clarity into the financial performance over the near to medium term. Given the continued uncertainty in many areas of the market on how quickly and to the extent they recover post shut down, we believe ought to provide a relative premium valuation for those companies that have more clarity into their operations and product demand. Lastly, we do believe that the medical device manufacturers are poised to be amongst the first segments of the broader market to participate as economies re-open, as pent up demand for elective surgeries such as hips, select cardiovascular procedures and many others, will be amongst the first areas that individuals return to.

We are not complacent to the broader market risks that remain as economies re-open and the uncertainty that accompanies further potential outbreaks or systemic shutdowns. However, while volatility has been at extreme levels, affording attractive premium generation on the covered call strategy, there have been several positives for the Healthcare sector that have been occurring during the unique current environment that we believe provide a robust backdrop for the companies held within the portfolio.

The Fund was invested in 20 Healthcare Leaders during the period and remains positioned for a recovery in sentiment within the sector. The Fund remains underweight the Tools and Diagnostics sub-sector that has very high relative valuations and remains market weight versus the benchmark in the Medical Equipment sub-sector, diversified across Pharmaceuticals, Biotechnology, and Health Care Services & Facilities. The Fund slightly reduced the biotechnology exposure during the period in favour of pharmaceutical exposure, adding exposure towards animal health. A positive from the enhanced volatility during the period is that the option premiums earned from the covered calls sold increase as volatility increases. The Fund sold call options on the underlying holdings during the period to meet its investment and income objectives.

RECENT DEVELOPMENTS

On March 10, 2020, the Fund began offering Series B Units. The Series B Units began trading under the symbol HHL.B. The Series B Units are designed for investors who want to maintain exposure to currency fluctuations of the foreign denominated holdings in the Fund compared to the Canadian dollar.

The recent spread of the coronavirus ("COVID-19") has caused volatility in the global financial markets and a slowdown in the global economy and may have a continued adverse impact on the financial performance of the Fund's investments. The extent of the overall impact to financial markets and the economy are highly uncertain and cannot be predicted as they will depend on the duration and renewed spread of the outbreak along with further government restrictions. If the financial markets and/or the overall economy are impacted for an extended period, the Fund's future investment results may be materially adversely affected.

RELATED PARTY TRANSACTIONS

There were no related party transactions during the reporting period, except for management fees and other expense reimbursements paid to Harvest, as noted below in Management and Other Fees.

Harvest Healthcare Leaders Income ETF

MANAGEMENT AND OTHER FEES

The Manager is responsible for managing the Fund's overall business and operations and provides key management personnel to the Fund. The Fund pays the Manager an annual management fee of 0.85%, plus applicable taxes, based on a percentage of the average daily net asset value ("NAV") of the Fund.

Operating expenses

The Fund is responsible for operating expenses relating to the carrying on of its business, including custodial services, interest, taxes, legal, audit fees, transfer agency services relating to the issue and redemption of units, and the cost of financial and other reports, costs and expenses for the Fund's Independent Review Committee ("IRC"), including fees and expenses of the IRC members and compliance with applicable laws, regulations and policies. The Manager pays for such expenses on behalf of the Fund, except for certain expenses such as interest, and is then reimbursed by the Fund.

Other expenses

The Manager will be reimbursed by the Fund for all reasonable costs, expenses and liabilities incurred by the Manager for performance of services on behalf of the Fund in connection with the discharge by the Manager of its duties hereunder. Such costs and expenses may include, without limitation: mailing and printing expenses for reports to unitholders and other unitholder communications; a reasonable allocation of salaries and benefits; and other administrative expenses and costs incurred in connection with the Fund's continuous public offering and other obligations. These expenses are allocated by the Manager on a reasonable basis, across all the Harvest Portfolios Group Inc. funds, and series of each applicable fund. These expenses were \$108,783 for the period ended June 30, 2020 (2019 - \$137,926) and are included in the unitholder reporting costs on the Statements of Comprehensive Income (Loss) in the financial statements.

Waivers and absorptions

At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. There were no management fee waivers or expense absorptions for the period ended June 30, 2020 or 2019. The management expense ratios of the Fund with and without the waivers and absorptions are reported in the Ratios and Supplemental Data table below.

RECOMMENDATIONS OR REPORTS BY THE INDEPENDENT REVIEW COMMITTEE

The Independent Review Committee tabled no special reports and made no extraordinary material recommendations to management of the Fund during the period ended June 30, 2020.

Harvest Healthcare Leaders Income ETF

FINANCIAL HIGHLIGHTS

The following tables present selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the period ended June 30, 2020 and past annual periods. This information is derived from the Fund's interim financial statements and past annual audited financial statements.

Series A

| THE FUND'S NET ASSETS PER UNIT | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|--|------------------|------------------|------------------|------------------|------------------|------------------|
| Net assets - beginning of the period | \$ 8.10 | \$ 7.80 | \$ 8.26 | \$ 7.91 | \$ 8.93 | \$ 9.23 |
| Increase (decrease) from operations | | | | | | |
| Total revenue | 0.09 | 0.15 | 0.17 | 0.16 | 0.17 | 0.19 |
| Total expenses | (0.05) | (0.09) | (0.10) | (0.12) | (0.12) | (0.13) |
| Realized gains (losses) for the period | 0.24 | - | 0.06 | 0.24 | 0.61 | (1.00) |
| Unrealized gains (losses) for the period | (0.59) | 0.99 | 0.08 | 0.58 | (0.95) | 1.13 |
| Total increase (decrease) from operations¹ | \$ (0.31) | \$ 1.05 | \$ 0.21 | \$ 0.86 | \$ (0.29) | \$ 0.19 |
| Distributions³ | | | | | | |
| From net investment income | (0.35) | (0.03) | - | - | - | - |
| From capital gains | - | - | (0.02) | - | - | - |
| Return of capital | - | (0.67) | (0.68) | (0.70) | (0.70) | (0.70) |
| Total annual distributions³ | \$ (0.35) | \$ (0.70) | \$ (0.70) | \$ (0.70) | \$ (0.70) | \$ (0.70) |
| Net assets - end of the period¹ | \$ 7.42 | \$ 8.10 | \$ 7.80 | \$ 8.26 | \$ 7.91 | \$ 8.93 |

| RATIOS AND SUPPLEMENTAL DATA | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Total net asset value (\$000's) | \$ 351,222 | \$ 351,883 | \$ 269,413 | \$ 244,316 | \$ 110,201 | \$ 137,229 |
| Number of units outstanding (000's) | 47,324 | 43,449 | 34,549 | 29,574 | 13,924 | 15,373 |
| Management expense ratio ⁴ | 1.08% | 1.12% | 1.15% | 1.24% | 1.37% | 3.76% |
| Management expense ratio before waivers or absorptions ⁴ | 1.08% | 1.12% | 1.15% | 1.24% | 1.37% | 3.76% |
| Trading expense ratio ⁵ | 0.15% | 0.15% | 0.15% | 0.13% | 0.10% | 0.11% |
| Portfolio turnover rate ⁶ | 48.60% | 61.04% | 46.92% | 42.77% | 40.47% | 52.25% |
| Net asset value per unit | \$ 7.42 | \$ 8.10 | \$ 7.80 | \$ 8.26 | \$ 7.91 | \$ 8.93 |
| Closing market price (HHL)* | \$ 7.43 | \$ 8.09 | \$ 7.77 | \$ 8.28 | \$ 7.92 | \$ 8.54 |

*On conversion to an ETF, the Fund traded under the symbol HHL. Prior to conversion the Fund traded under the symbol HHL.UN as a closed end fund.

Series B

| THE FUND'S NET ASSETS PER UNIT | 2020 |
|--|------------------|
| Net assets - beginning of the period² | \$ 8.00 |
| Increase (decrease) from operations | |
| Total revenue | 0.05 |
| Total expenses | (0.03) |
| Realized gains (losses) for the period | 0.46 |
| Unrealized gains (losses) for the period | (0.41) |
| Total increase (decrease) from operations¹ | \$ 0.07 |
| Distributions³ | |
| From net investment income | (0.23) |
| From capital gains | - |
| Return of capital | - |
| Total annual distributions³ | \$ (0.23) |
| Net assets - end of the period¹ | \$ 7.90 |

Harvest Healthcare Leaders Income ETF

Series B (continued)

| RATIOS AND SUPPLEMENTAL DATA | 2020 |
|---|-----------------|
| Total net asset value (\$000's) | \$ 1,185 |
| Number of units outstanding (000's) | 150 |
| Management expense ratio ⁴ | 1.08% |
| Management expense ratio before waivers or absorptions ⁴ | 1.08% |
| Trading expense ratio ⁵ | 0.15% |
| Portfolio turnover rate ⁶ | 48.60% |
| Net asset value per unit | \$ 7.90 |
| Closing market price (HHL.B) | \$ 7.84 |

Series U (CAD)

| THE FUND'S NET ASSETS PER UNIT | 2020 | 2019 | 2018 | 2017 |
|--|------------------|------------------|------------------|------------------|
| Net assets - beginning of the period² | \$ 10.64 | \$ 10.68 | \$ 10.29 | \$ 10.40 |
| Increase (decrease) from operations | | | | |
| Total revenue | 0.13 | 0.21 | 0.22 | 0.17 |
| Total expenses | (0.06) | (0.13) | (0.13) | (0.13) |
| Realized gains (losses) for the period | 0.81 | 0.04 | 0.56 | 0.11 |
| Unrealized gains (losses) for the period | (0.75) | 0.84 | 0.56 | (0.36) |
| Total increase (decrease) from operations¹ | \$ 0.13 | \$ 0.96 | \$ 1.21 | \$ (0.21) |
| Distributions³ | | | | |
| From net investment income | (0.48) | (0.09) | - | - |
| From capital gains | - | - | (0.55) | - |
| Return of capital | - | (0.84) | (0.36) | (0.83) |
| Total annual distributions³ | \$ (0.48) | \$ (0.93) | \$ (0.91) | \$ (0.83) |
| Net assets - end of the period^{1, 7} | \$ 10.33 | \$ 10.64 | \$ 10.68 | \$ 10.29 |

| RATIOS AND SUPPLEMENTAL DATA | 2020 | 2019 | 2018 | 2017 |
|---|------------------|------------------|------------------|------------------|
| Total net asset value (\$000's) | \$ 32,009 | \$ 43,638 | \$ 38,450 | \$ 25,471 |
| Number of units outstanding (000's) | 3,100 | 4,100 | 3,600 | 2,475 |
| Management expense ratio ⁴ | 1.09% | 1.11% | 1.15% | 1.22% |
| Management expense ratio before waivers or absorptions ⁴ | 1.09% | 1.11% | 1.15% | 1.22% |
| Trading expense ratio ⁵ | 0.15% | 0.15% | 0.15% | 0.15% |
| Portfolio turnover rate ⁶ | 48.60% | 61.04% | 46.92% | 42.77% |
| Net asset value per unit | \$ 10.33 | \$ 10.64 | \$ 10.68 | \$ 10.29 |
| Closing market price - USD (HHL.U) | \$ 7.50 | \$ 8.16 | \$ 7.82 | \$ 8.23 |

Explanatory Notes:

- Net assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the reporting period. It is not intended that the Fund's net assets per unit table act as a continuity of opening and closing net assets per unit.
- Series U commenced operations on February 3, 2017 with net assets of \$10.40 (\$8.00 USD). Series B commenced operations on March 10, 2020 with a net asset value per unit of \$8.00.
- Distributions were paid in cash or reinvested in additional units of the Fund.
- Management expense ratio ("MER") is based on total expenses (excluding commissions and other portfolio transaction costs) of the stated period and is expressed as an annualized percentage of the daily average net asset value during the period. The Series A MER for the period December 31, 2015 included agents' fee of \$2,551,893 and issue costs of \$655,355. These costs are treated as one-time expenses and therefore were not annualized. The MER without these costs was 1.33%.

Harvest Healthcare Leaders Income ETF

5. The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net asset value during the period. In 2020 the calculation was modified to include certain transaction costs charged by the custodian. The trading expense ratio in prior periods was not re-stated.
6. The Fund's portfolio turnover rate indicates how actively the Fund's portfolio advisor manages its portfolio investments. A portfolio turnover of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher a Fund's portfolio turnover rate, the greater the trading costs payable by the Fund and the greater the chance of an investor receiving taxable capital gains. There is not necessarily a relationship between a high turnover rate and the performance of a Fund.
7. The USD amount of the net assets at the end of the period was \$7.61 USD.

Harvest Healthcare Leaders Income ETF

Past Performance

The performance information presented herein assumes all dividends of the Fund during the periods presented were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemptions, or other charges that would have reduced returns or affected performance. Past performance of the Fund is not necessarily indicative of how it will perform in the future.


YEAR-BY-YEAR RETURNS

The following charts present the Fund's performance for each of the years shown and illustrate how the Fund's performance varied for Series A and Series U. The chart shows, in percentage terms, how much an investment made on the first day of each financial year would have grown or decreased by the last day of each financial year except for 2020 which represents the interim period.

The performance of Series B is not shown as National Instrument 81-106, the regulatory guideline for Continuous Disclosure, does not permit reporting of performance for any fund series that has been in existence less than one year.


Fund Performance

Series A



2014 represents the period from December 18 to December 31

Series U (USD)



2017 represents the period from February 3 to December 31

Harvest Healthcare Leaders Income ETF

SUMMARY OF INVESTMENT PORTFOLIO

The major portfolio categories and top holdings of the Fund at the end of the period are indicated in the following tables. A detailed breakdown of the Fund's holdings is available in the "Schedule of Investments" section of the Fund's interim financial statements.

As at June 30, 2020

| Top Holdings | % of Net Asset Value |
|---------------------------------------|----------------------|
| Zoetis Inc., Class A | 5.2 |
| Sanofi S.A. ADR | 5.1 |
| AbbVie Inc. | 5.1 |
| Boston Scientific Corporation | 4.9 |
| Amgen Inc. | 4.9 |
| Novartis AG ADR | 4.9 |
| HCA Healthcare, Inc. | 4.8 |
| Stryker Corporation | 4.8 |
| Medtronic PLC | 4.8 |
| Gilead Sciences, Inc. | 4.8 |
| Abbott Laboratories | 4.8 |
| Pfizer Inc. | 4.8 |
| Bristol-Myers Squibb Company | 4.8 |
| Merck & Co., Inc. | 4.7 |
| Johnson & Johnson | 4.7 |
| Anthem, Inc. | 4.7 |
| Eli Lilly and Company | 4.7 |
| UnitedHealth Group Incorporated | 4.7 |
| AstraZeneca PLC ADR | 4.6 |
| GlaxoSmithKline PLC ADR | 4.6 |
| Cash and other assets and liabilities | 3.3 |
| Foreign currency forward contracts | 0.7 |
| Options | (0.4) |
| Total | 100.0 |

This summary of investment portfolio may change due to the ongoing portfolio transactions of the Fund. Quarterly updates of the Fund's investment portfolio are available from Harvest Portfolios Group Inc. at www.harvestportfolios.com.

Harvest Healthcare Leaders Income ETF

SECTOR ALLOCATION

| Sector | % of Net Asset Value |
|---------------------------------------|-----------------------------|
| Health Care | 96.4 |
| Cash and other assets and liabilities | 3.3 |
| Foreign currency forward contracts | 0.7 |
| Options | (0.4) |
| Total | 100.0 |

GEOGRAPHIC ALLOCATION

| Country of Risk | % of Net Asset Value |
|---------------------------------------|-----------------------------|
| United States | 77.2 |
| United Kingdom | 9.2 |
| France | 5.1 |
| Switzerland | 4.9 |
| Cash and other assets and liabilities | 3.3 |
| Foreign currency forward contracts | 0.7 |
| Options | (0.4) |
| Total | 100.0 |

Harvest Healthcare Leaders Income ETF

Securities classification:

| Investments at fair value as at June 30, 2020 | | | | |
|---|--------------------|------------------|--------------|--------------------|
| | Level 1 (\$) | Level 2 (\$) | Level 3 (\$) | Totals (\$) |
| Financial Assets | | | | |
| Equities | | | | |
| Common Stock | 296,584,504 | - | - | 296,584,504 |
| ADR | 74,057,946 | - | - | 74,057,946 |
| Derivatives | | | | |
| Foreign currency forward contracts | - | 2,724,944 | - | 2,724,944 |
| Total Financial Assets | 370,642,450 | 2,724,944 | - | 373,367,394 |
| Financial Liabilities | | | | |
| Derivatives | | | | |
| Options | (1,504,470) | - | - | (1,504,470) |
| Foreign currency forward contracts | - | (4,144) | - | (4,144) |
| Total Financial Liabilities | (1,504,470) | (4,144) | - | (1,508,614) |

| Investments at fair value as at December 31, 2019 | | | | |
|---|--------------------|------------------|--------------|--------------------|
| | Level 1 (\$) | Level 2 (\$) | Level 3 (\$) | Totals (\$) |
| Financial Assets | | | | |
| Equities | | | | |
| Common Stock | 327,593,176 | - | - | 327,593,176 |
| ADR | 57,405,457 | - | - | 57,405,457 |
| Derivatives | | | | |
| Foreign currency forward contracts | - | 4,556,731 | - | 4,556,731 |
| Total Financial Assets | 384,998,633 | 4,556,731 | - | 389,555,364 |
| Financial Liabilities | | | | |
| Derivatives | | | | |
| Options | (843,617) | - | - | (843,617) |
| Total Financial Liabilities | (843,617) | - | - | (843,617) |

There were no Level 3 securities held by the Fund as at June 30, 2020 and December 31, 2019, and there were no transfers between Level 1 and Level 2 for the period ended June 30, 2020 and 2019.

The value of the equities and options is based on quoted prices. The value of the foreign currency forward contract is determined as the difference between the contract rate and the current forward rate at the measurement date applied to the contract's notional amount and adjusted for counterparty risk.

Concentration Risk

Concentration risk arises as a result of the concentration of exposures within the same category, whether it is geographical location, product type, industry, sector or counterparty type. The following is a summary of the Fund's concentration risk by country and industry in which the companies held in the portfolio operate.



Head Office

610 Chartwell Rd, Suite 204
Oakville, Ontario L6J 4A5

Phone Number: 416.649.4541

Toll Free: 866.998.8298

Fax Number: 416.649.4542

Email: info@harvestportfolios.com

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This document may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events. By their nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. We caution readers of this document not to place undue reliance on our forward-looking statements as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed or implied in the forward-looking statements. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including but not limited to market and general economic conditions, interest rates, regulatory and statutory developments, the effects of competition in the geographic and business areas in which the Fund may invest and the risks detailed from time to time in the Fund's prospectus or offering memorandum. We caution that the foregoing list of factors is not exhaustive and that when relying on forward-looking statements to make decisions with respect to investing in the Fund, investors and others should carefully consider these factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements. Due to the potential impact of these factors, the Fund does not undertake, and specifically disclaims, any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.